目次

Executive Summary
Market overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Product
Market segments
Comparison by Product
Combination therapy - Market size and forecast 2020-2025
Monotherapy - Market size and forecast 2020-2025
Market opportunity by Product

Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Exela Pharma Sciences LLC
GlaxoSmithKline Plc
Merck and Co. Inc.
Novartis AG
SHIONOGI Co. Ltd.
Sumitomo Dainippon Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Product - Market share 2020-2025 (%)
22: Comparison by Product
23: Combination therapy - Market size and forecast 2020-2025 ($ million)
24: Combination therapy - Year-over-year growth 2020-2025 (%)
25: Monotherapy - Market size and forecast 2020-2025 ($ million)
26: Monotherapy - Year-over-year growth 2020-2025 (%)
27: Market opportunity by Product
28: Customer landscape
29: Market share By Geographical Landscape 2020-2025 (%)
30: Geographic comparison
31: North America - Market size and forecast 2020-2025 ($ million)
32: North America - Year-over-year growth 2020-2025 (%)
33: Europe - Market size and forecast 2020-2025 ($ million)
34: Europe - Year-over-year growth 2020-2025 (%)
35: Asia - Market size and forecast 2020-2025 ($ million)
36: Asia - Year-over-year growth 2020-2025 (%)
37: ROW - Market size and forecast 2020-2025 ($ million)
38: ROW - Year-over-year growth 2020-2025 (%)
39: Key leading countries
40: Market opportunity By Geographical Landscape ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: AstraZeneca Plc - Overview
48: AstraZeneca Plc - Product and service
49: AstraZeneca Plc - Key offerings
50: AstraZeneca Plc - Key customers
51: AstraZeneca Plc - Segment focus
52: Boehringer Ingelheim International GmbH - Overview
53: Boehringer Ingelheim International GmbH - Business segments
54: Boehringer Ingelheim International GmbH - Key offerings
55: Boehringer Ingelheim International GmbH - Key customers
56: Boehringer Ingelheim International GmbH - Segment focus
57: Exela Pharma Sciences LLC- Overview
58: Exela Pharma Sciences LLC- Product and service
59: Exela Pharma Sciences LLC- Key offerings
60: Exela Pharma Sciences LLC- Key customers
61: Exela Pharma Sciences LLC- Segment focus
62: GlaxoSmithKline Plc - Overview
63: GlaxoSmithKline Plc - Business segments
64: GlaxoSmithKline Plc - Key offerings
65: GlaxoSmithKline Plc - Key customers
66: GlaxoSmithKline Plc - Segment focus
67: Merck and Co. Inc. - Overview
68: Merck and Co. Inc. - Business segments
69: Merck and Co. Inc. - Key offerings
70: Merck and Co. Inc. - Key customers
71: Merck and Co. Inc. - Segment focus
72: Novartis AG - Overview
73: Novartis AG - Business segments
74: Novartis AG - Key offerings
75: Novartis AG - Key customers
76: Novartis AG - Segment focus
77: SHIONOGI Co. Ltd. - Overview
78: SHIONOGI Co. Ltd. - Business segments
79: SHIONOGI Co. Ltd. - Key offerings
80: SHIONOGI Co. Ltd. - Key customers
81: SHIONOGI Co. Ltd. - Segment focus
82: Sumitomo Dainippon Pharma Co. Ltd. - Overview
83: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
84: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
85: Sumitomo Dainippon Pharma Co. Ltd. - Key customers
86: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
87: Teva Pharmaceutical Industries Ltd. - Overview
88: Teva Pharmaceutical Industries Ltd. - Business segments
89: Teva Pharmaceutical Industries Ltd. - Key offerings
90: Teva Pharmaceutical Industries Ltd. - Key customers
91: Teva Pharmaceutical Industries Ltd. - Segment focus
92: Viatris Inc. - Overview
93: Viatris Inc. - Business segments
94: Viatris Inc. - Key offerings
95: Viatris Inc. - Key customers
96: Viatris Inc. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations